Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002168 · ClinicalTrials.gov registry record · NA
Determining Lipid Content in Stool After Alpha-cyclodextrin
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03002168: Completed NA study, sponsored by Mayo Clinic.
NCT03002168 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002168, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss. The Investigator will conduct the study and analyze the samples at Mayo Clinic in Rochester, Minnesota.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Alpha-cyclodextrin
- RADIATION Triolein radiolabeled with 100 microcuries of 3^Hydrogen
- RADIATION Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2017-06-05 |
| Phase | NA |
What the finished NCT03002168 record still lists
NCT03002168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03002168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03002168 about?
NCT03002168 is a clinical study titled "Determining Lipid Content in Stool After Alpha-cyclodextrin". The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss. The Investigator will cond...
What is the current status of trial NCT03002168?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-01-20. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT03002168?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Alpha-cyclodextrin (DIETARY_SUPPLEMENT), Triolein radiolabeled with 100 microcuries of 3^Hydrogen (RADIATION), Tripalmitin radiolabeled with 20 microcuries of 14^Carbon (RADIATION).
Who is sponsoring clinical trial NCT03002168?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03002168's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI